Document is current
Any future updates will be listed below
-
Authors
Campbell, Noll L. https://orcid.org/0000-0002-8933-9339
Holden, Richard J.
Gao, Sujuan
Unverzagt, Frederick W.
Lane, Kathleen A.
Carter, Allie
Harrington, Addison B.
Manoharan, Sneha
Manoharan, Neha
Rosenthal, Danielle L.
Pitts, Christopher
Pelkey, Kathryn
Papineau, Emily
Lauck, David M.
Keshk, Noha
Alamer, Khalid
Khalil, Hussein
Boustani, Malaz A.
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01AG061452)
- License Information
-
More Information
Article History
Received: 29 July 2024
Accepted: 7 November 2024
First Online: 22 November 2024
Declarations
:
: All procedures have received and maintained ethical approval from the Institutional Review Board of the Indiana University (IRB# 1811254189; Federal-Wide Assurance Number, FWA00003544). The trial has also been registered at ClinicalTrials.gov (Identifier: NCT04270474).
: Not applicable—no identifying images or other personal or clinical details of individual participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request.
: Dr. Boustani serves as a Chief Scientific Officer and co-Founder of Blue Agilis; the Chief Health Officer of DigiCare Realized, Inc; and the Chief Health Officer of Mozyne Health, Inc. He has equity interest in Blue Agilis, Inc; DigiCare Realized, Inc; and Mozyne Health, Inc. He sold his equity in Preferred Population Health Management LLC and MyShift, Inc (previously known as RestUp, LLC). He serves as an advisory board member or consultant for Eli Lilly and Co; Eisai, Inc; Merck & Co Inc; Biogen Inc; and Genentech Inc. These conflicts have been reviewed by Indiana University and has been appropriately managed to maintain objectivity. All other authors report no conflicts of interest.
